Most Profitable NASDAQ Biotechnology Companies

Net Income
Net IncomeEfficiencyMarket RiskExp Return
1AZN AstraZeneca PLC ADR
6.9 B
(0.32)
 1.46 
(0.46)
2AMGN Amgen Inc
6.72 B
(0.15)
 1.55 
(0.24)
3GILD Gilead Sciences
5.61 B
 0.20 
 1.43 
 0.28 
4SNY Sanofi ADR
5.4 B
(0.16)
 1.23 
(0.20)
5GMAB Genmab AS
4.35 B
(0.29)
 1.51 
(0.44)
6ROIV Roivant Sciences
4.23 B
(0.05)
 1.53 
(0.07)
7REGN Regeneron Pharmaceuticals
3.95 B
(0.40)
 1.71 
(0.68)
8VRTX Vertex Pharmaceuticals
3.62 B
(0.03)
 1.68 
(0.05)
9BNTX BioNTech SE
1.19 B
 0.08 
 3.50 
 0.27 
10BIIB Biogen Inc
1.16 B
(0.32)
 1.30 
(0.41)
11RPRX Royalty Pharma Plc
1.13 B
(0.09)
 1.02 
(0.09)
12UTHR United Therapeutics
984.8 M
 0.03 
 1.74 
 0.05 
13INCY Incyte
597.6 M
 0.14 
 2.26 
 0.31 
14JAZZ Jazz Pharmaceuticals PLC
414.83 M
 0.03 
 1.96 
 0.06 
15ALKS Alkermes Plc
355.76 M
(0.01)
 2.30 
(0.01)
16MEDP Medpace Holdings
282.81 M
(0.12)
 2.90 
(0.35)
17HALO Halozyme Therapeutics
281.59 M
(0.15)
 3.64 
(0.53)
18NBIX Neurocrine Biosciences
249.7 M
(0.12)
 2.90 
(0.35)
19GLPG Galapagos NV ADR
211.7 M
 0.06 
 2.40 
 0.14 
20EXEL Exelixis
207.76 M
 0.19 
 2.40 
 0.46 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors. Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.